TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02862080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathode tsDCS
Description: Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathode tsDCS
Description: Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso
Description: Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso
Description: Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso
Description: Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
Study: NCT01349153

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook-based Self-help Comparison
Description: Twelve weekly messages and a pedometer.
Study: NCT00557557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: 5-FU
Description: Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Oxaliplatin
Description: 40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
Study: NCT03388268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vancomycin
Description: Oral vancomycin 125mg 4 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar liquid manufactured to mimic oral vancomycin 125mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toxin enzyme immunoassay
Description: EIA assay: Wampole/Tech Lab Tox A/B II

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Toxin enzyme immunoassay
Description: EIA assay: Wampole/Tech Lab Tox A/B II

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nuceleic acid amplification test
Description: NAAT: Xpert C. difficile, Cepheid

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nuceleic acid amplification test
Description: NAAT: Xpert C. difficile, Cepheid
Study: NCT02960087

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose rate brachytherapy
Description: I-125 to a total dose of 144 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High dose rate brachytherapy
Description: 27 Gy in 2 fractions
Study: NCT02226861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 selection system
Description: Stem cells will be selected with the CliniMACS system before transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ULD IL-2
Description: sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution
Study: NCT01484431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil- Tablet or Oral suspension
Description: Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.
Study: NCT01612598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo PCI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo PCI
Study: NCT01516255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide
Description: 0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Injected subcutaneously. Subjects are randomly allocated to two treatment sequences

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected subcutaneously. Subjects are randomly allocated to two treatment sequences

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrocardiogram (ECG)
Description: 24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: electrocardiogram (ECG)
Description: 24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electrocardiogram (ECG)
Description: Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: electrocardiogram (ECG)
Description: Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected
Study: NCT03915847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single layer closure
Description: Uterine incision will be approximated with continuous unlocked suture, including a narrow band of the endometrial layer, without trimming incision edges.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double layer closure
Description: The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Doble layer closure with trimming
Description: Uterine incision will be trimmed and old scar tissue will be removed. The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
Study: NCT02381093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified BLS course
Description: BLS using CI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard BLS Course
Description: Usual BLS teaching
Study: NCT01502683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No aortic clamping
Description: No aortic clamp used in this group. The aortic clamp is a standard cardiac surgical instrument used during cardiac operations, not a specific device used for this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial occluding clamp
Description: The partial-occluding clamp is a standardized instrument used during coronary artery bypass surgery, it is not a specific device for this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single cross clamp
Description: The proximal anastomoses performed under single clamp is an alternative method during coronary artery bypass surgery. The single clamp essentially means that whole operation is done using the cross clamp, which is a standard instrument during cardiac operations, not a specific device for this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cross clamp and partial occluding clamp
Description: Both an aortic cross clamp and partial occluding clamp are used in this arm. Neither the cross clamp nor the partial clamp are specific devices for this study but are standard cardiac surgical instruments used during coronary artery bypass surgery and cardiac surgery.
Study: NCT03581604

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Allergy work-up
Description: Allergy work-up

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples
Study: NCT03468062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients assigned in Dexmedetomidine or Placebo group are given Dexmedetomidine or normal saline after induction of anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients assigned in Dexmedetomidine or Placebo group are given Dexmedetomidine or normal saline after induction of anesthesia.
Study: NCT00666900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Strength IDP-107
Description: Once a day for 12 weeks
Study: NCT03198013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT00666900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Strength IDP-107
Description: Once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Once a day for 12 weeks
Study: NCT02976077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RC2S+
Description: new cognitive remediation program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active comparator
Description: cognitive remediation program
Study: NCT00601263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Asthma Herbal Medical Intervention (ASHMI)
Description: We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-Asthma Herbal Medical Intervention (ASHMI)
Description: We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Asthma Herbal Medical Intervention (ASHMI)
Description: We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-Asthma Herbal Medical Intervention (ASHMI)
Description: We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Asthma Herbal Medical Intervention (ASHMI)
Description: We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-Asthma Herbal Medical Intervention (ASHMI)
Description: We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
Study: NCT00623259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-mBN120B
Study: NCT02244970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
Study: NCT03134677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 2 ml of hyperbaric bupivacaine (0.5%) was given intrathecally to patients in a sitting position by midline attempt between the L3 and L4 intervertebral space.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: General anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
Study: NCT01423591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inactive powder
Description: Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
Study: NCT01549704

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).~Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine.

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).~Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: please see intervention description for ropivacaine

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: please see intervention description for ropivacaine
Study: NCT04262167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lung Spheroid Stem Cells 100 million
Description: LSCs grown from autologous trans-bronchial biopsy specimens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lung Spheroid Stem Cells 200 million
Description: LSCs grown from autologous trans-bronchial biopsy specimens
Study: NCT01363570

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
Study: NCT01805453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg\*2/day until the halting for any reason

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
Study: NCT00140010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin beta
Description: 30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage
Study: NCT01824927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First eye (FE)
Description: Phacoemulsification cataract extraction surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First eye (FE)
Description: Phacoemulsification cataract extraction surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second eye (SE)
Description: Phacoemulsification cataract extraction surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second eye (SE)
Description: Phacoemulsification cataract extraction surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids eye drops
Description: Use steroids eye drops to decrease the pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids eye drops
Description: Use steroids eye drops to decrease the pain.
Study: NCT00357110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg oral tablet
Study: NCT02239874

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D and fish oil placebo
Description: Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil and vitamin D placebo
Description: 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D placebo and fish oil placebo
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D and fish oil
Description: Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
Study: NCT02388126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T multiparametric MRI
Description: Magnetom Verio 3T, Erlangen, Germany

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound
Description: Bk Medical Pro Focus Ultraview 2202 system
Study: NCT00961467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid, Melphalan, Prednisone, Thalidomide
Description: Thalidomide was administered at 50 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid, Melphalan, Prednisone, Thalidomide
Description: Thalidomide was administered at 100 mg/day.
Study: NCT03312023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]
Description: 1 pill once daily for 12 weeks for Group A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]
Description: 1 pill once daily for 12 weeks for Group A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 MG [Sovaldi]
Description: 1 pill once daily for 12 weeks for Group C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90 MG
Description: 1 pill once daily for 12 weeks for Group D
Study: NCT04393194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Cream with Applicator [Dose Form]
Description: Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal Cream with Applicator [Dose Form]
Description: Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.
Study: NCT03011567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive acetaminophen for postpartum mild pain relief

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive acetaminophen for postpartum mild pain relief

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Participants will receive ibuprofen for postpartum mild pain relief

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Participants will receive ibuprofen for postpartum mild pain relief
Study: NCT02897050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1200mg/m2/d, po, d1-d21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (tablet)
Description: Cyclophosphamide 50 mg/d, po, d1-d21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Fluorouracil 500mg/m2, iv, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 500mg/m2, iv, d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin 100mg/m2, iv, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 100mg/m2, iv, d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (injection)
Description: Cyclophosphamide 500mg/m2, iv, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (injection)
Description: Cyclophosphamide 500mg/m2, iv, d1
Study: NCT02274805

Intervention type: PROCEDURE
Intervention: Adults presenting for surgery in the neck area
Study: NCT03916679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MESO CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-MESO CARs